Toggle navigation
Home
Products
Dexolve
Services
Feasibility
Pipeline
News
Staff
Career
Search
Log In / Register
€
$
News
New data on efficacy and stability of Mavenclad
News
17 September, 2019
Merck announced the presentation of new data proving the long-term efficacy and stability of Mavenclad (HPBCD formulated cladribine) against relapsing forms of multiple sclerosis.
Read more on Cyclodextrin News blog
https://cyclodextrinnews.com/2019/09/16/new-real-world-data-support-long-term-efficacy-and-safety-profile-of-mavenclad/
BACK TO NEWS